Treatment of portopulmonary hypertension - Isn't it time to move forward?

Liver Transplantation

Volumn 14, Issue 3, 2008, Pages 270-271

  Swanson, Karen L ^a  

^a Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; NITRIC OXIDE; PHOSPHODIESTERASE V; PROSTACYCLIN;

DISEASE SEVERITY; EDITORIAL; ENZYME INHIBITION; HEART CATHETERIZATION; HEART OUTPUT; HEMODYNAMIC MONITORING; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; PORTOPULMONARY HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; VASODILATATION;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER DISEASES; LIVER TRANSPLANTATION; PULMONARY ARTERY;

EID: 41149111906     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.21365     Document Type: Editorial

References (12)

1. Austin MJ, McDougall NI, Wendon JA, Sizer E, Knisely AS, Rela M, et al. Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl 2008;14:287-291.
2. Benza RL, Park MH, Keogh A, Girgis RE. Management of pulmonary arterial hypertension with a focus on combination therapies. J Heart Lung Transplant 2007;26:437-446.
3. Mathai SC, Girgis RE, Fisher MR, Champion HC, Housten-Harris T, Zaiman A, et al. Addition of sildenafil to bosentan monotherapy in pulmonary arterial hypertension. Eur Respir J 2007;29:469-475; comment 432-434.
4. Humbert M, Barst RJ, Robbins IM, Channick RN, Galiè N, Boonstra A, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004;24:353-359.
5. Halank M, Kolditz M, Miehlke S, Schiemanck S, Schmeisser A, Hoeffken G. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan. Wien Med Wochenschr 2005;155:376-380.
6. Golbin JM, Krowka MJ. Portopulmonary hypertension. Clin Chest Med 2007;28:203-218.
7. Krowka MJ, Swanson KL, Frantz RP, McGoon MD, Wiesner RH. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006;44:1502-1510.
8. Puri A, McGoon MD, Kushwaha SS. Pulmonary arterial hypertension: current therapeutic strategies. Nat Clin, Pract Cardiovasc Med 2007;4:319-329.
9. Hoeper MM, Seyfarth HJ, Hoeffken G, Wirtz H, Spiekerkoetter E, Pletz MW, et al. Experience with inhaled iloprost and bosentan in portopulmonary hypertension. Eur Respir J 2007. doi:10.1183/09031936.00032407. Available at: http://erj.ersjournals.com.
10. Fix OK, Bass NM, De Marco T, Merriman RB. Long-term follow-up of portopulmonary hypertension: effect of treatment with epoprostenol. Liver Transpl 2007;13:875-885.
11. Ashfaq M, Chinnnakotla. S, Rogers L, Ausloos K, Saadeh S, Klintmalm GB, et al. The impact of treatment of portopulmonary hypertension on survival following liver transplantation. Am J Transplant 2007;7:1258-1264.
12. Sussman N, Kaza V, Barshes N, Stribling R, Goss J, O'Mahony C, et al. Successful liver transplantation following medical management of portopulmonary hypertension: a single-center series. Am J Transplant 2006;6:2177-2182.